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planations for the different mortality results 
of the ERSPC and PLCO trials (3,4).
For this analysis, we used the microsim-
ulation screening analysis (MISCAN) model 
for  prostate  cancer  (5,6),  which  simulates 
individual  life  histories  and  models  the   
development of cancer in individuals as a 
sequence  of  tumor  states.  The  model 
includes 18 detectable preclinical states in 
the natural history of prostate cancer that 
are derived from combinations of clinical T 
stage (T1, impalpable; T2, palpable, con-
fined  to  the  prostate;  and  T3+,  palpable, 
with  extensions  beyond  the  prostatic 
capsule) (7), differentiation grade (well dif-
ferentiated, Gleason score 2–6; moderately 
differentiated, Gleason score 7; and poorly 
differentiated, Gleason score 8–10) (8), and 
metastatic stage (local or regional [M0] and 
distant [M1]) (7). Cancer can progress from 
each preclinical state to the clinical disease 
state  (ie,  become  diagnosed  because  of 
symptoms) (Supplementary Figure 1, avail-
able  online).  Preclinical  cancers  may  be 
detected by PSA screening. Screen detec-
tion depends on the timing of PSA tests and 
on  the  test  sensitivity.  In  the  MISCAN 
model, the PSA test and a subsequent bi-
opsy are modeled as a single test; therefore, 
PSA test sensitivity also depends on whether 
a positive test is followed by a biopsy. In the 
model, sensitivity is defined as the proba-
bility that a preclinical tumor is detected by 
a screening test at the time the test is taken. 
The parameters for PSA test sensitivity are 
stage specific because the sensitivity of a test 
primarily depends on the size of the tumor.
Model parameters, including transition 
probabilities,  mean  dwelling  times  (the 
time from one preclinical state to another 
preclinical  or  clinical  state),  and  stage- 
specific test sensitivities, are typically esti-
mated as follows. A model is constructed 
for  a  specific  situation,  such  as  prostate 
cancer incidence in the United States or in 
both  arms  of  the  ERSPC–Rotterdam. 
Parameters are then estimated by numer-
ical minimization of the deviance between 
observed numbers of cases and the number 
of cases predicted by the model. Deviances 
are calculated by assuming a Poisson likeli-
hood for incidence data or by assuming a 
multinomial likelihood for stage distribution 
data.
Prostate-specific  antigen  (PSA)  testing 
was  introduced  in  the  United  States  in 
1986 to monitor prostate cancer progres-
sion. The test was rapidly adopted for the 
early detection of prostate cancer, and as a 
consequence,  the  incidence  of  prostate 
cancer  has  increased  rapidly  since  1988, 
peaking  in  1992  (1).  The  benefits  and 
harms of PSA testing depend on its per-
formance  in  detecting  prostate  cancers 
and  on  the  benefits  of  consequent  early 
treatment.  The  performance  of  PSA 
testing as a screening test depends on the 
cutoff  level  for  recommending  a  biopsy, 
the compliance to a biopsy recommenda-
tion,  and  the  diagnostic  accuracy  of  the 
biopsies that are performed.
Differences between PSA screening per-
formance with respect to the detection of 
prostate cancer in a trial and in a population 
are crucial information for translating the 
results of a prostate cancer screening trial to 
a population setting. In this study, we com-
pared  PSA  screening  performance  for 
detecting prostate cancers in the US popu-
lation with that in the Rotterdam section of 
the  European  Randomized  Study  of 
Screening  for  Prostate  Cancer  (ERSPC–
Rotterdam). Because PSA screening perfor-
mance in the US Prostate, Lung, Colorectal 
and Ovarian (PLCO) trial may be compa-
rable with PSA screening performance in 
the US population (2), the results of this 
analysis could also provide quantitative ex-
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than  in  ERSPC–Rotterdam.  For  example,  for  nonpalpable  local-  or  regional-stage 
cancers  (ie,  stage  T1M0),  the  estimates  of  PSA  test  sensitivity  were  0.26  in  the 
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screening  in  detecting  prostate  cancer  was  lower  in  the  United  States  than  in 
ERSPC–Rotterdam.
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In  this  study,  we  first  developed  an 
ERSPC model that simulated the prostate 
cancer  progression  and  screening  in 
ERSPC–Rotterdam.  Estimates  of  natural 
history  parameters  and  test  sensitivities 
were obtained by using the observed detec-
tion rates, interval cancer rates, and stage 
distributions  from  ERSPC–Rotterdam 
(5,6). The parameter estimates of the model 
are  presented  in  Supplementary  Table  1 
(available  online),  and  the  observed  data 
used  for  the  estimation  are  presented  in 
Supplementary Table 2 (available online).
Next, to make the model results compa-
rable with observed US data, the popula-
tion in the model was adjusted to the US 
population  by  replacing  the  birth  tables 
and life tables with US-specific tables, and 
the  screening  protocol  of  ERSPC–
Rotterdam was replaced with the frequency 
of PSA testing in the US population. The 
frequency  of  PSA  testing  in  the  United 
States  was  modeled  according  to  the  ap-
proach  described  by  Mariotto  et  al.  (9). 
The frequency of a first PSA test and of 
repeat tests in the United States, as repro-
duced in the MISCAN model, is illustrated 
in  Figure  1.  On  average,  80%  of  the 
screened men in the United States have a 
repeat PSA test within 2 years of the pre-
vious test.
We  considered  two  US  models.  In 
model  1,  we  investigated  the  hypothesis 
that PSA screening in the United States is 
the same as in ERSPC–Rotterdam. In this 
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Prior knowledge
The benefits and harms of prostate-specific 
antigen (PSA) testing depend on its perfor-
mance in detecting prostate cancers and on 
the benefits of consequent early treatment. 
The  performance  of  PSA  testing  as  a 
screening test depends on the cutoff level 
for  recommending  a  biopsy,  the  compli-
ance to a biopsy recommendation, and the 
diagnostic accuracy of the biopsies that are 
performed.  Translating  the  results  of  a 
prostate cancer screening trial to a popula-
tion setting requires a comparison of PSA 
screening performance for the detection of 
prostate cancer in these two situations.
Study design
A microsimulation screening analysis model 
for prostate cancer and PSA screening was 
developed  for  the  European  Randomized 
Study  of  Screening  for  Prostate  Cancer 
(ERSPC)–Rotterdam trial and then adapted 
to the US population by replacing demogra-
phy parameters with US-specific ones and 
the  trial  screening  protocol  with  the 
frequency of PSA tests in the US popula-
tion.  The  natural  progression  of  prostate 
cancer and the sensitivity of a PSA test fol-
lowed by a biopsy were assumed to be the 
same in the United States as in the trial.
Contribution
The  model-predicted  prostate  cancer  inci-
dence peak in the United States was sub-
stantially higher than the observed prostate 
cancer incidence peak. However, the actual 
observed  incidence  was  reproduced  by   
assuming  a  substantially  lower  PSA  test 
sensitivity  in  the  United  States  than  in 
ERSPC–Rotterdam.
Implications
PSA screening in the United States detected 
fewer prostate cancers than PSA screening in 
the European trial because of the lower sen-
sitivity of PSA testing followed by biopsy.
Limitations
Other factors that differed between the US 
and  ERSPC–Rotterdam  populations  and 
might  influence  the  detection  rates  were 
not taken into account. The model used for 
the frequency of PSA testing included diag-
nostic tests. The model did not explain the 
steep drop in prostate cancer incidence in 
the United States after 1992. The reliability 
of  the  sensitivity  estimates  could  not  be 
determined.
From the Editors
 
Figure 1. Frequency of first prostate-specific antigen (PSA) tests and 
repeat  tests  in  the  US  population  as  generated  by  microsimulation 
screening analysis (MISCAN). The frequencies are for men aged 50–84 
years.
model, all prostate cancer–related parame-
ters were the same as in the ERSPC model. 
In model 2, we investigated the hypothesis 
that the sensitivity of PSA screening in the 
United States is lower than that in ERSPC–
Rotterdam. In this model, all prostate cancer– 
related  parameters  except  for  the  test 
sensitivity  parameters  were  the  same  as 
those  in  the  ERSPC  model.  US-specific 
estimates of test sensitivities were obtained 
by  using  observed  age-specific  incidence 
and age-specific stage distribution (local or 
regional vs distant) in the US population. 
For estimation of the US-specific parame-
ters, we used data from the Surveillance, 
Epidemiology,  and  End  Results  (SEER) 
registry for US men aged 50–84 years who 
were  diagnosed  with  prostate  cancer 
between  January  1,  1985,  and  December 
31, 2000. The data were based on the nine 
core  catchment  areas  (SEER  9)  of  the 
SEER  registry  (http://seer.cancer.gov/). 
We used the test sensitivity parameter esti-
mates  of  the  ERSPC  model  as  starting 
values for optimization of the estimates of 
the  US  model.  The  estimated  test  sensi-
tivity  parameters  of  the  calibrated  model 
are presented in Table 1 and the observed 
data used for calibrating the model are pre-
sented in Supplementary Table 3 (available 
online).
In  model  1,  both  the  predicted  and 
observed incidence peaks occurred in 1992. 
However,  the  predicted  prostate  cancer 
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substantially  higher  than  the  observed 
prostate cancer incidence peak (13.3 vs 8.1 
cases per 1000 man-years), which suggests 
a lower detection of prostate cancer in the 
United States than in ERSPC–Rotterdam 
(Figure 2). In model 2, the predicted inci-
dence peak was the same size as the observed 
incidence peak (Figure 2). However, esti-
mates of test sensitivity were lower in the 
United States than in ERSPC–Rotterdam. 
For  example,  for  nonpalpable  local-  or 
regional-stage  cancers  (ie,  stage  T1M0), 
the estimates of PSA test sensitivity were 
0.26  in  the  United  States  vs  0.94  in 
ERSPC–Rotterdam (Table 1).
The lower sensitivity of PSA screening 
in  the  United  States  compared  with 
ERSPC–Rotterdam  in  model  2  could  be 
due to a higher PSA cutoff level for recom-
mending  biopsy  in  the  United  States,  a 
lower biopsy compliance rate in the United 
States, or a lower sensitivity of the biopsies 
in the United States. The latter possibility 
is unlikely because more biopsy cores are 
generally taken in the United States than 
were  taken  in  ERSPC–Rotterdam.  The 
other  two  possibilities  might  explain  the 
lower sensitivity of PSA screening in the 
United  States.  A  higher  PSA  cutoff  level 
for  recommending  biopsy  in  the  United 
States could follow from the fact that the 
recommended  PSA  cutoff  level  in  the 
United States is 4 ng/mL, whereas the PSA 
cutoff  level  in  ERSPC–Rotterdam  was   
3 ng/mL. A lower biopsy compliance rate 
in  the  United  States  could,  for  instance, 
indicate that some physicians in the United 
States might have used a higher PSA cutoff 
level than recommended (ie, higher than 4 
ng/mL) or might have advised a confirma-
tory PSA test if the first PSA level was ele-
vated. Confirmatory PSA tests would lower 
the  biopsy  compliance  rate  because  men 
with  a  PSA  level  higher  than  the  cutoff 
level at the first test but with a PSA level 
lower than the cutoff level at the confirma-
tory test would probably be advised to not 
have a biopsy; therefore, some men with a 
PSA level higher than the cutoff level at the 
first  PSA  test  would  not  have  a  biopsy. 
Pinsky et al. (2) reported a biopsy compli-
ance rate in the PLCO trial of 41% within 
1 year of a positive PSA test. They sug-
gested that this biopsy compliance rate is 
representative  of  US  screening  practice, 
given  that  men  with  a  positive  PSA  test   
in the PLCO trial were referred to their 
Table 1. Estimates of sensitivity, detection rate, and deviance for the two US models*
Item Model 1 Model 2
Sensitivity by stage†
  T1M0 0.94 0.26
  T2M0 0.94 0.26
  T3M0 1.00 0.27‡
  T1M1 0.96 0.84
  T2M1 0.97 0.84
  T3M1 1.00 0.84
Detection rate per 1000 screened men
  At first PSA test 62 18
  At repeat PSA test 13 12
Deviance 44 727 23 438
*  PSA = prostate-specific antigen.
†  T1, T2, and T3 are the three clinical T stages (T1, nonpalpable; T2, palpable, confined to the prostate; and 
T3, palpable, with extensions beyond the prostatic capsule); M0 is the local or regional stage; and M1 is 
the distant stage.
‡  The range of plausible values is 0.24–0.29. The range of plausible values indicates a range in which 
the 95% confidence interval will be with near certainty, see Supplementary Figure 2 (available online). 
Because of restrictions on the sensitivities (sensitivity increases with clinical T stage and metastatic 
state), this range cannot be calculated for the other parameters.
Figure 2. Observed and predicted age-adjusted incidence per 1000 man-
years for men aged 50–84 years in the US models. In model 1, prostate-
specific antigen (PSA) screening in the US population is the same as in 
the Rotterdam section of the European Randomized Study of Screening 
for Prostate Cancer (ERSPC–Rotterdam). In model 2, the sensitivity of 
PSA screening is lower in the US population than in ERSPC–Rotterdam.
personal  physician  for  follow-up.  In  the 
screening arm of ERSPC–Rotterdam, bi-
opsies were administered by the screening 
center at no charge to the subject, and re-
minders for biopsy appointments were sent 
if necessary, resulting in a biopsy compli-
ance rate of approximately 90%. In model 
2, the detection rates at first PSA screening 
and at repeat PSA screening were 18 and 
12  per  1000  screened  men,  respectively 
(Table 1), which are comparable with the 
detection  rates  at  the  first  round  of 
screening (16 per 1000 screened men) and 
repeat  screening  (11  per  1000  screened 
men) in the PLCO trial (10).
This  study  has  four  limitations.  First, 
we did not take into account other factors, 
such as race, that differed between the US 
and  ERSPC–Rotterdam  populations  and 
might  influence  the  detection  rates. 
Approximately 10% of the US population 
is  black,  whereas  nearly  100%  of  the 
ERSPC–Rotterdam population was white. 
Because  the  incidence  of  prostate  cancer 
was higher among black men than among 
white  men  during  the  study  period  (11), jnci.oxfordjournals.org    JNCI | Brief Communication 355
these  racial  differences  might  explain  the 
different detection rates estimated for the 
two  populations.  However,  the  incidence 
of prostate cancer among whites in the US 
population was similar to the overall inci-
dence (11), which indicates that the effect 
of black men on the overall observed inci-
dence was small, as was their effect on the 
outcomes of this study.
Second, we assumed that the model that 
we used for the frequency of PSA testing 
(9) would apply to screening tests. During 
the  construction  of  that  model,  all  fol-
low-up PSA tests taken after diagnosis as 
well as PSA tests occurring within 3 months 
of  a  previous  PSA  test  were  eliminated. 
However, a fraction of the remaining tests 
might be diagnostic tests that were used to 
confirm  a  suspicion  for  prostate  cancer. 
The size of this fraction is unknown, but 
including this fraction of diagnostic tests as 
screening tests would imply that the actual 
screening rate is lower than in the model.
Third, a weakness of our model is that it 
fails  to  explain  why  prostate  cancer  inci-
dence  in  the  United  States  dropped  so 
steeply after 1992 (Figure 2). In our model, 
the cancers detected in repeat tests led to a 
slower decline of incidence after 1992 than 
what was observed. However, the frequency 
of repeat PSA testing remained at a level of 
30% (Figure 1), and it is unclear why these 
tests  detected  so  little  cancer  in  the  US 
population.
Fourth,  we  could  not  compute  95% 
confidence intervals for the sensitivity pa-
rameters: Because of random noise in the 
simulated  predictions  and  restrictions  on 
the  sensitivities  (sensitivity  increases  with 
clinical T stage and metastatic state), for-
mal 95% confidence intervals are difficult 
to obtain when using the microsimulation 
model. However, for fixed values of other 
model  parameters,  the  range  of  plausible 
values  for  test  sensitivity  for  a  local  or   
regional stage tumor in clinical stage T3 
(ie, in state T3M0) was narrow (0.24–0.29). 
The range of plausible values contains with 
near  certainty  a  standard  computed  95% 
confidence interval. The calculation of the 
range  of  plausible  values  is  presented  in 
Supplementary Figure 2 (available online).
In  conclusion,  PSA  screening  in  the 
United States did not detect as many pros-
tate cancers as PSA screening in ERSPC–
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Rotterdam because of the lower sensitivity 
of PSA testing followed by a biopsy. The 
consequence of this lower test sensitivity is 
that  the  effects  of  PSA  screening  in  the 
United States are likely to be different from 
those observed in the ERSPC–Rotterdam. 
For example, Draisma et al. (12) noted that 
the lead time (time by which screening ad-
vances  diagnosis)  and  the  frequency  of 
overdiagnosis were smaller in the United 
States  than  in  ERSPC–Rotterdam  (mean 
non-overdiagnosed  lead  time:  6.9  vs  7.9 
years;  overdiagnosis  frequency:  42%  vs 
66%),  indicating  that  the  harms  of  PSA 
testing in the United States, although still 
substantial, are likely to be less than those 
in the ERSPC–Rotterdam. The benefits of 
PSA screening in the United States are also 
likely to be different from those in ERSPC–
Rotterdam.  The  ERSPC  trial  has  shown 
that screening for prostate cancer by using 
PSA tests can reduce prostate cancer mor-
tality  (4);  however,  we  cannot  directly 
translate these mortality reductions to the 
US  population  because  of  differences 
between the two populations, such as the 
lower sensitivity of PSA screening in the 
United  States.  Finally,  this  analysis  also 
shows  quantitatively  that  it  is  likely  that 
there is a difference in the sensitivity of the 
PSA screening (PSA test followed by a bi-
opsy)  in  the  ERSPC  and  PLCO  trials, 
which is likely to have contributed to the 
different outcomes of the trials.
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